Updated 11 July 2026.
The quiet structural news of 2026 is that GLP-1 weight-loss medicine has entered the NHS GP contract. Under the 2026/27 QOF arrangements, English practices can earn reported payments of up to £3,000 a year for tirzepatide (Mounjaro) prescribing to eligible patients, with around £1,000 more attached to weight-management programme referrals and a reported £25 million ring-fenced behind it. The numbers are modest per practice; the signal is not. Weight-loss injections have moved from private novelty to mainstream primary care in under three years.
For private practitioners this reframes the market rather than shrinking it. NHS provision targets eligibility thresholds and will run waiting lists; private clinics compete on access, titration support, monitoring quality and the aesthetic aftermath of rapid weight loss. That last part is the growth area our GLP-1 face guide covers: volume restoration and skin-quality demand tracks the prescribing curve with a lag measured in months.
It also raises the governance bar. When GPs prescribe the same drug under contract, sloppy private prescribing stands out to regulators, and the MHRA’s enforcement record on illegal weight-loss medicine sales shows appetite. If weight-management clinic work is on your roadmap, the GLP-1 clinic course is built governance-first for exactly this environment.
QOF figures are as reported in 2026 GP-contract coverage.